Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 09 02:33PM ET
3.15
Dollar change
+0.20
Percentage change
6.78
%
Index- P/E- EPS (ttm)-0.04 Insider Own86.20% Shs Outstand73.83M Perf Week5.35%
Market Cap232.56M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.19M Perf Month1.61%
Income3.54M PEG- EPS next Q- Inst Own1.96% Short Float0.40% Perf Quarter-2.63%
Sales0.00M P/S- EPS this Y- Inst Trans1.77% Short Ratio1.36 Perf Half Y140.46%
Book/sh-0.01 P/B- EPS next Y- ROA4.89% Short Interest0.04M Perf Year-69.54%
Cash/sh0.06 P/C54.98 EPS next 5Y- ROE5.37% 52W Range0.95 - 25.00 Perf YTD-30.77%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-87.40% Beta2.47
Dividend TTM- Quick Ratio3.18 Sales past 5Y0.00% Gross Margin- 52W Low231.58% ATR (14)0.28
Dividend Ex-Date- Current Ratio3.18 EPS Y/Y TTM38.53% Oper. Margin0.00% RSI (14)50.91 Volatility8.99% 8.19%
Employees7 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-146.93% Payout- Rel Volume0.55 Prev Close2.95
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume29.97K Price3.15
SMA201.88% SMA500.14% SMA200-36.44% Trades Volume12,935 Change6.78%
Mar-19-24 10:57AM
07:00AM
Mar-11-24 02:26PM
07:00AM
Jan-31-24 08:30AM
08:30AM Loading…
Nov-02-23 08:30AM
Oct-30-23 08:39AM
Oct-11-23 08:30AM
Oct-06-23 09:29AM
08:30AM
Sep-22-23 09:01AM
Sep-20-23 05:40PM
Sep-13-23 08:30AM
Sep-07-23 04:30PM
Aug-31-23 04:05PM
08:30AM Loading…
Aug-16-23 08:30AM
Conduit Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of clinical assets to address the unmet medical needs of patients, through exclusive relationships. Its medical needs in the areas of autoimmune disease and idiopathic male infertility. The company is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heilbron Jack KendrickFormer CEO,director&10% ownerSep 22 '23Option Exercise0.004,060,25004,060,250Sep 26 05:30 PM